
## Michael M Givertz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7666122/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM. ASAIO Journal, 2022, 68, 374-383.	0.9	8
2	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 17.	3.0	77
3	Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374.	2.9	34
4	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	0.7	23
5	Evolving Characteristics of Heart Transplantation Donors and Recipients. Journal of the American College of Cardiology, 2022, 79, 1108-1123.	1.2	16
6	Trends and Outcomes of Left Ventricular Assist Device Therapy. Journal of the American College of Cardiology, 2022, 79, 1092-1107.	1.2	41
7	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	0.7	12
8	The role of sensitization in post-transplant outcomes in adults with congenital heart disease sensitization in adults with congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 2022, , 100384.	0.2	0
9	T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathy. American Journal of Transplantation, 2021, 21, 1465-1476.	2.6	10
10	Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. Journal of Physiology and Biochemistry, 2021, 77, 295-304.	1.3	0
11	Letter by DeFilippis et al Regarding Article, "Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young― Circulation: Heart Failure, 2021, 14, e008033.	1.6	0
12	Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. ESC Heart Failure, 2021, 8, 1915-1923.	1.4	12
13	Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study. Circulation: Heart Failure, 2021, 14, e007892.	1.6	7
14	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	0.7	7
15	Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. Clinical Transplantation, 2021, 35, e14424.	0.8	6
16	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	1.6	12
17	Proinflammatory TH17 cytokine activation, disease severity and outcomes in peripartum cardiomyopathy. International Journal of Cardiology, 2021, 339, 93-98.	0.8	4
18	Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 2021, 7, e17.	1.2	18

#	Article	IF	CITATIONS
19	Abstract 11074: Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response. Circulation, 2021, 144, .	1.6	0
20	Acute heart failure. Trends in Cardiovascular Medicine, 2020, 30, 104-112.	2.3	62
21	Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. Clinical Cardiology, 2020, 43, 43-49.	0.7	14
22	Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691.	2.9	33
23	B cell clonal expansion within immune infiltrates in human cardiac allograft vasculopathy. American Journal of Transplantation, 2020, 20, 1431-1438.	2.6	12
24	Virtual Health During a Pandemic. Circulation: Heart Failure, 2020, 13, e007317.	1.6	6
25	Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiology, 2020, 5, 1048.	3.0	58
26	Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses. Journal of Heart and Lung Transplantation, 2020, 39, 1191-1194.	0.3	31
27	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. Journal of Cardiac Failure, 2020, 26, 727-732.	0.7	7
28	Sacubitril/Valsartan in Advanced HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	1.9	39
29	Considerations for HeartÂFailure Care During the COVID-19 Pandemic. JACC: Heart Failure, 2020, 8, 681-691.	1.9	89
30	An Emergency Medicine–focused Summary of the HFSA/SAEM/ISHLT Clinical Consensus Document on the Emergency Management of Patients With Ventricular Assist Devices. Academic Emergency Medicine, 2020, 27, 618-629.	0.8	0
31	Sex Differences in Exercise Capacity and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of the RELAX and NEAT-HFpEF Trials. Journal of Cardiac Failure, 2020, 26, 276-280.	0.7	14
32	Marijuana Use in Patients With CardiovascularÂDisease. Journal of the American College of Cardiology, 2020, 75, 320-332.	1.2	91
33	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENAâ€HF trial. European Journal of Heart Failure, 2020, 22, 1451-1461.	2.9	12
34	Challenges in Heart Transplantation in the Era of COVID-19. Circulation, 2020, 141, 2048-2051.	1.6	47
35	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	0.7	16
36	HFSA/SAEM/ISHLT clinical expert consensus document on the emergency management of patients with ventricular assist devices. Journal of Heart and Lung Transplantation, 2019, 38, 677-698.	0.3	18

#	Article	IF	CITATIONS
37	HFSA/SAEM/ISHLT Clinical Expert Consensus Document on the Emergency Management of Patients with Ventricular Assist Devices. Journal of Cardiac Failure, 2019, 25, 494-515.	0.7	16
38	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	1.2	37
39	Advanced HeartÂFailure Therapies forÂAdults With CongenitalÂHeartÂDisease. Journal of the American College of Cardiology, 2019, 74, 2295-2312.	1.2	32
40	Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
41	Peripartum cardiomyopathy. BMJ: British Medical Journal, 2019, 364, k5287.	2.4	99
42	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	1.3	54
43	Marijuana use and candidacy for heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 589-592.	0.3	7
44	Electrocardiographic findings in peripartum cardiomyopathy. Clinical Cardiology, 2019, 42, 524-529.	0.7	29
45	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961983736.	0.7	10
46	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. New England Journal of Medicine, 2019, 380, 1606-1617.	13.9	266
47	Clinical Course of Patients With Worsening Heart Failure With ReducedÂEjection Fraction. Journal of the American College of Cardiology, 2019, 73, 935-944.	1.2	160
48	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	0.7	4
49	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. Open Forum Infectious Diseases, 2019, 6, S5-S5.	0.4	0
50	Mobile Geolocation Technology to Improve Multidisciplinary Care of Patients With Ventricular Assist Devices: A Feasibility Study. Critical Pathways in Cardiology, 2019, 18, 47-50.	0.2	0
51	Testing Medical Fairness. Circulation: Heart Failure, 2019, 12, e006517.	1.6	1
52	Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. American Journal of Perinatology, 2019, 36, 476-483.	0.6	12
53	Sizing it up in heart transplantation: Time to change the guidelines?. Journal of Heart and Lung Transplantation, 2019, 38, 133-135.	0.3	5
54	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528.	2.6	11

#	Article	IF	CITATIONS
55	Comparing CMR Mapping Methods andÂMyocardial Patterns Toward HeartÂFailure Outcomes in NonischemicÂDilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 1659-1669.	2.3	80
56	Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2019, 47, 375-383.	1.0	2
57	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. Journal of Thrombosis and Thrombolysis, 2019, 47, 57-66.	1.0	2
58	Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. Circulation, 2019, 139, 155-168.	1.6	113
59	Treating Gout in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 1005-1008.	1.2	4
60	Cerebrovascular Accidents During Mechanical Circulatory Support. Stroke, 2018, 49, 1197-1203.	1.0	21
61	Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 2018, 24, 281-302.	0.7	280
62	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191.	0.8	157
63	Prevalence of polyreactive innate clones among graft-Âɨnfiltrating B cells in human cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2018, 37, 385-393.	0.3	30
64	Expanding the Donor Pool With Use of Hepatitis C Infected Hearts. Circulation: Heart Failure, 2018, 11, e005656.	1.6	8
65	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	3.8	187
66	Disparities in Wait-List Outcomes for Adults With Congenital Heart Disease Listed for Heart Transplantation Before and Since Revision of Status I Listing. American Journal of Cardiology, 2018, 122, 1761-1764.	0.7	3
67	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. Journal of Cardiac Failure, 2018, 24, 682-694.	0.7	70
68	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2018, 46, 180-185.	1.0	16
69	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. Circulation: Heart Failure, 2018, 11, e004644.	1.6	58
70	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	11
71	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	1.2	74
72	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738.	2.9	34

#	Article	IF	CITATIONS
73	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. JAMA - Journal of the American Medical Association, 2017, 317, 1958.	3.8	329
74	SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. Catheterization and Cardiovascular Interventions, 2017, 89, E233-E247.	0.7	32
75	Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. Catheterization and Cardiovascular Interventions, 2017, 89, 1294-1299.	0.7	4
76	Executive Summary of the SCAI/HFSA Clinical Expert Consensus Document on the Use of Invasive Hemodynamics for the Diagnosis and Management of Cardiovascular Disease. Journal of Cardiac Failure, 2017, 23, 487-491.	0.7	11
77	Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	1.6	38
78	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of Cardiac Failure, 2017, 23, 628-651.	0.7	531
79	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	1.2	2,256
80	Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517.	1.9	78
81	A heart within a heart. Catheterization and Cardiovascular Interventions, 2017, 89, 1239-1241.	0.7	0
82	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 1875-1886.	1.2	198
83	Early aspirin use and the development of cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2017, 36, 1344-1349.	0.3	39
84	Evolving Areas in Heart Transplantation. JACC: Heart Failure, 2017, 5, 869-878.	1.9	33
85	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320.	2.9	53
86	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	3.0	199
87	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	1.3	8
88	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	0.7	30
89	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1 (	).784314 0.7	rgBT /Overloc
90	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences, 2017, 18, 1470.	1.8	17

#	Article	IF	CITATIONS
91	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931.	0.8	10
92	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	2.9	162
93	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	2.9	69
94	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839.	2.9	70
95	Turning Failure into Success: Trials of the Heart Failure Clinical Research Network. Current Cardiology Reports, 2016, 18, 121.	1.3	3
96	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Failure Society of America. Circulation, 2016, 134, e282-93.	1.6	494
97	Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. Current Heart Failure Reports, 2016, 13, 111-118.	1.3	4
98	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	1.2	549
99	Cancer and the Heart: Training Subspecialists, Optimizing Care, and Moving the Field Forward. Journal of Cardiac Failure, 2016, 22, 472-474.	0.7	2
100	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	38
101	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975.	0.8	6
102	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	0.8	53
103	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	0.8	11
104	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2016, 316, 500.	3.8	457
105	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	80
106	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	2.9	32
107	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
108	Advanced Therapies for Advanced Heart Failure: Time to Raise Awareness. Heart Failure Clinics, 2016, 12, ix-x.	1.0	0

#	Article	IF	CITATIONS
109	Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050.	2.9	49
110	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627.	0.7	4
111	Thrombus around the redesigned HeartWare HVAD inflow cannula: A pathologic case series. Journal of Heart and Lung Transplantation, 2016, 35, 926-930.	0.3	26
112	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. Current Emergency and Hospital Medicine Reports, 2016, 4, 93-97.	0.6	3
113	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35
114	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171.	0.8	34
115	Variable Contribution of Heart Failure toÂQuality of Life in Ambulatory HeartÂFailure With Reduced, Better, orÂPreserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 184-193.	1.9	48
116	Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy. JACC: Heart Failure, 2016, 4, 380-388.	1.9	68
117	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	0.8	35
118	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	1.5	32
119	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706.	2.9	24
120	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the) Tj ETQq0 C	0 rgBT /C 0.7	overlock 10 T 108
121	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology, 2015, 11, 585-595. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical	0.5	23
122	circulatory support devices in cardiovascular care (Endorsed by the American heart assocation, the) Tj ETQq0 0 0	rgBT /Ove 0.7	rlock 10 Tf 5 25
123	E175-96. Pump thrombosis redux. Journal of Heart and Lung Transplantation, 2015, 34, 1511-1514.	0.3	12
124	Assessing the liver to predict outcomes in heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 869-872.	0.3	8
125	Arrhythmias in Peripartum Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 309-317.	0.7	29
126	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation, 2015, 131, 1763-1771.	1.6	239

#	Article	IF	CITATIONS
127	2015 SCAI/ACC/HFSA/STS Clinical ExpertÂConsensus Statement on the Use ofÂPercutaneous Mechanical Circulatory SupportÂDevices in Cardiovascular Care. Journal of the American College of Cardiology, 2015, 65, 2140-2141.	1.2	78
128	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. Journal of the American College of Cardiology, 2015, 65, e7-e26.	1.2	491
129	statement on the use of percutaneous mechanical circulatory support devices in Cardiovascular Care (Endorsed by the American heart association, the Cardiological society of India, and Sociedad Latino) Tj ETQq1 1	0.784314 0.7	rgBT /Overl
130	and Cardiovascular Interventions, 2015, 85, 1112-1114. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	0.7	283
131	Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403.	1.9	44
132	Left ventricular dimension decrement index early after axial flow assist device implantation: A novel risk marker for late pump thrombosis. Journal of Heart and Lung Transplantation, 2015, 34, 1561-1569.	0.3	5
133	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2015, 21, 674-693.	0.7	39
134	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	0.7	73
135	Predicting Outcomes in Heart Transplantation. Circulation: Cardiovascular Imaging, 2014, 7, 857-859.	1.3	1
136	What is Old is Now New: Insights into Cardiorenal Physiology. Journal of Cardiac Failure, 2014, 20, 920-922.	0.7	0
137	Assessment and Management of Heart Failure After Left Ventricular Assist Device Implantation. Circulation, 2014, 129, 1161-1166.	1.6	27
138	Response to Sexton: Inhibiting the Renin–Angiotensin–Aldosterone System in Patients With Heart Failure and Renal Dysfunction. Circulation: Heart Failure, 2014, 7, 537-540.	1.6	4
139	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 372-381.	0.3	26
140	Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. Journal of Heart and Lung Transplantation, 2014, 33, 215-217.	0.3	3
141	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293.	1.0	276
142	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0	) OorgBT /C	overakock 10⊺
143	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67.	1.6	60

144Discharge Outcomes in Patients With Paracorporeal Biventricular Assist Devices. Annals of Thoracic<br/>Surgery, 2014, 97, 894-900.0.78

#	Article	IF	CITATIONS
145	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. Circulation: Heart Failure, 2013, 6, 862-868.	1.6	21
146	Epidemiology and Natural History of Recovery of Left Ventricular Function in Recent Onset Dilated Cardiomyopathies. Current Heart Failure Reports, 2013, 10, 321-330.	1.3	68
147	The Challenge of Drug Development in Acute Heart Failure. JACC: Heart Failure, 2013, 1, 442-444.	1.9	3
148	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 1268.	3.8	976
149	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	0.7	53
150	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533.	3.8	410
151	Peripartum Cardiomyopathy. Circulation, 2013, 127, e622-6.	1.6	30
152	Mechanical Circulatory Support for Advanced Heart Failure. Circulation, 2012, 125, 1304-1315.	1.6	182
153	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine, 2012, 367, 2296-2304.	13.9	790
154	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 913-933.	0.3	210
155	Heart Failure With Recovered Ejection Fraction: A Distinct Clinical Entity. Journal of Cardiac Failure, 2011, 17, 527-532.	0.7	134
156	Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-Year follow-up from a randomized, controlled study. Journal of Heart and Lung Transplantation, 2011, 30, 1200-1201.	0.3	17
157	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 364, 797-805.	13.9	1,363
158	Ventricular Assist Devices. Circulation, 2011, 124, e305-11.	1.6	63
159	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	0.7	1,086
160	Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Journal of the American College of Cardiology, 2008, 51, 2301-2309.	1.2	350
161	Therapeutic Strategies in Heart Failure. Circulation, 2008, 118, .	1.6	Ο
162	Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction. Circulation, 2007, 115, 1218-1224.	1.6	66

#	Article	IF	CITATIONS
163	Response to Letter Regarding Article, "Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationshipsâ€ <del>.</del> Circulation, 2007, 116, .	1.6	0
164	The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance. Journal of the American College of Cardiology, 2007, 50, 1551-1560.	1.2	162
165	Metabolic Cardiomyopathy, 2nd ed Circulation, 2004, 110, .	1.6	Ο
166	Antioxidants and Myocardial Contractility. Circulation, 2001, 103, 782-783.	1.6	44
167	Secondary Pulmonary Hypertension in Chronic Heart Failure. Circulation, 2000, 102, 1718-1723.	1.6	366